7-30-04

JUL 2 9 280%

PHA 42624.1 (01380/5/US) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Diane T. Stephenson et al. Serial No. 10/829,000 Filed April 21, 2004

For COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS

July 29, 2004

P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R.1.56, applicants submit the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. In accordance with the OG notice of August 5, 2003 partially waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied. Applicants submit herewith copies of the foreign patent documents and literature references.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the date of mailing of this Information Disclosure Statement, the Commissioner is hereby

PHA 42624.1 (01380/5/US) PATENT

authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.

Respectfully submitted,

Edward Heilek, Reg. No. 31,525

SENNIGER, POWERS, LEAVITT & ROEDEL

One Metropolitan Square, 16th Floor

St. Louis, Missouri 63102

(314) 231-5400

EJH/cms
*Enclosures

Mail Stop Amendment Express Mail Label No. EV 416452976 US

	PTO/SB	/08A			Complete if Known			
	IN	FORMATION	DISC	LOSURE	Application Number	10/829,000		
		TATEMENT B			Filing Date	April 21, 2004		
	10(160	as many she	ets as	necessary)	Confirmation Number			
/	0112				First Named Inventor	Diane T. Stephenson		
19	JUL 2 9 200	4 2			Group Art Unit			
ES .					Examiner Name	·		
	Sheet	1	of	4	Attorney Docket No.	PHA 42624.1 (01380/5/US)		

U.S. PATENT DOCUMENTS										
		U.S. Patent Doc	ument		Date of Publication of Cited Document MM-DD-YYYY					
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document						
3,7 1	1	3,261,859		Knoll AG.	07/19/1966					
	2	3,267,104		Janssen Pharmaceutica N.V.	08/16/1966					
	3	4,338,322		Sato	07/06/1982					
-	4	4,466,972		Neumann	08/21/1984					
	5	4,521,537		Kosley, Jr. et al.	06/04/1985					
-	6	4,652,561		Mohacsi et al.	03/24/1987					
	7	4,663,325		Ohtaka et al.	05/05/1987					
	8	4,572,909		Campbell et al.	02/25/1986					
	9	4,678,783		Hidaka et al.	07/07/1987					
	10	4,845,225		Schwender et al.	07/04/1989					
	11	4,935,417		Pascal et al.	06/19/1990					
	12	5,314,903		Axelsson et al.	05/24/1994					
	13	5,466,823		Talley et al.	11/14/1995					
	14	5,521,207		Graneto	05/28/1996					
	15	5,633,272		Talley et al.	05/27/1997					

Examiner Date Signature Considere	d
-----------------------------------	---

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/08A						Complete if Known				
l INI	FORMA	TION F	מפור	LOSURE		Ar	oplication Number	10	/829,000	
				PLICANT		Filing Date			April 21, 2004	
luse	as man	v sheet	te ae	necessary)	Ì		onfirmation Number			
(430	as man	y Silect	io ao	necessary)	ŀ		rst Named Inventor	Di	ane T. Stephenson	
								, Di	and 1. Gtophonoon	
					}		roup Art Unit			
Sheet	Sheet 2 of 4					Attorney Docket No. PHA 42624.1 (01380/5/US)				
	16	5,767,1	29				Yuen		06/16/1998	
	17	5,932,5				_	Talley et al.	•	08/03/1999	
	18	5,981,5	-				Axelsson et al.	-	11/09/1999	
	19	6,034,2	256				Carter et al.		03/07/2000	
•	20	6,077,8	350				Carter et al.		06/20/2000	
	21	6,306,9	12				Mueller		10/23/2001	
	22	6,387,8	97				Snutch		05/14/2002	
	23 6,423,689					Booth et al.			07/23/2002	
•				FOREIG	N PA	TE	NT DOCUMENTS			
Examiner Initials*	No.¹ Office Number⁴ Code (if		Kind Code ²		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	T _e		
	24	EP	007	2620 /	A1		Recordati S.A.		07/09/1982	
	25	EP	008	9167 /	A2		Pfizer Limited		03/08/1983	
	26	EP	009	2936	A1		Taisho Pharmaceutical Co. Ltd		04/13/1983	
	27	EP	012	5803 /	A2	_	Fisons Plc		04/16/1984	
	28	EP	013	2375 /	A2		Pfizer Limited		07/18/1984	
	29	EP	014	5434	A2		Otsuka Pharmaceutical Co., Ltd	d.	12/03/1984	
	30	EP	017	3933 (abs) [/]	A1		Satinger, Gerhard, Dr.		08/23/1985	
Examiner Signature							Date Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

PTO/SB/08A						Complete if Known				
l IN	IFORMA	TION	DISC	LOSURE		Application Number 10/829,000				
				PLICANT	Ì	Filing Date April 21, 2004				
(use	as man	v shee	ets as	s necessary)	ľ	Confirmation Number				
(400	ao man	, O1100	no ac	, 110000001, 3 /	•	First Named Inventor Diane T. Stephenson				
						Group Art Unit				
ļi					-					
			<u> </u>			Examiner Name				
Sheet	3		of	4		Attorney Docket No. PHA 42624.1 (01380/5/US)				
				· · · · · ·						
	31	EP	018	34257	A1	Janssen Pharmaceutica N.V. 11/22/1985				
	32	EP	021	8996	A2	Yason S.r.L. 10/01/1986				
	· 33 EP 0257616 A2		A2	The Green Cross Corporation 08/25/1987						
	34	EP	035	8418	A1	Sankyo Company Limited 09/01/1989				
•	35	EP	036	66548	A1	Yuhan Corporation Ltd. 10/25/1989				
	36 EP 0372934 A2		A2	The Wellcome Foundation Limited 12/06/1989						
	37 EP 0372940 A2		A2	Allergan, Inc. 12/07/1989						
	38 EP 0400495 A1		A1	Farmitalia Carlo Erba S.r.L. 05/25/1990						
	. 39 EP 0404359 A1		A1	Pfizer Limited 05/25/1990						
	40 EP 0414421 A2		A2	Richter Gedeon Vegyeszeti Gyar R.T. 08/09/1990						
	41 EP 0424901 A1		A1	The Green Cross Corporation 10/24/1990						
	42	EP	044	1539	A2	Tanabe Seiyaku Co., Ltd. 01/31/1991				
	43	EP	046	7435	A2	Akzo N.V. 06/20/1991				
	44	EP	052	0200	A2	Neurosearch A/S 05/27/1992				
	45	EP	055	9569	A1	Bristol-Myers Squibb Company 03/04/1993				
	46	wo	91/	07980	A1	Neurex Corporation 06/13/1991				
	47	wo	92/	01672	A1	Novo Nordisk A/S 02/06/1992				
	48	wo	92/	04338	A1	The UpJohn Company 03/19/1992				
	49	wo	92/	14709	A2	Cambridge Neuroscience Inc. 09/03/1992				

1		 	
	Examiner	Date	
	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

PTO/SB	/08A						Complete if Known				
INFORMATION DISCLOSURE							Application Number 10/829,000				
				PLICANT		Fi	lling Date	Ap	April 21, 2004		
luse	as man	v shae	ate ac	necessary)		C	onfirmation Number	- <u>-</u> -			
(usc	as man	ly Silec	olo as	incocssary)		<u> </u>	rst Named Inventor	Di	ane T. Stephenson		
						┢			ane 1. Otephenson		
						┝	roup Art Unit				
	1		r			E	xaminer Name				
Sheet	4		of	4		A	Attorney Docket No.		PHA 42624.1 (01380/5/US)		
	50	1,40	T	27445					20444000	T	
	50	wo	+	07415	A1		Universite De Montreal		03/14/1996	+	
	51	wo		07641 (abs) 45115	A1		Nippon Shinyaku Co., Ltd.		03/14/1996	+	
•	52	wo	-)3484	A1		Trophix Pharmaceuticals, Inc. Merck Frosst Canada Inc.		01/29/1998	+	
•	54	wo	+	54350	A1		The University of Queensland		10/28/1999	-	
	55	wo		55688	A1		Warner-Lambert Company		11/04/1999	 	
	56	wo		24719	A1		Abbott Laboratories		05/04/2000	T	
	57	wo	1	18584	A2		Ortho-McNeil Pharmaceutical,	Inc.	08/24/2000	\dagger	
	. I	OT	HER	ART - NON	PATE	EN'	LITERATURE DOCUM	IEN	TS		
Examiner Initials*	Cite No.1	Includ	de nam	e of the author ((in CAP	ITAI seria	L LETTERS), title of the article (val, symposium, catalog, etc.) date er, city and/or country where pul	vhen e, pag	appropriate), title of the ge(s), volume-issue	T6	
	DE VRIES et al, "The Antiinflammatory Activity of Topically Applied Novel Calcium-Channel Antagonists", Inflammation, 1995, 19(2): 261-275										
	59						the Neuronal Ca ² + channel bloc Pharmacology, 2000, 408: 241-		LY042826 and		
	60	KRAT	ZER et	al, "Simulation	of Prima	ary I	Haemostasis in Vitro", Haemosta	sis, 1	1985, 15: 357-362		
	61	Hydro	chlorid	e, a Novel Calcii	ùm Cha	nne	no)pentanoic Acid [4,4-Bis(4-fluo Il Antagonist, Is Ifficacious in Sev 3(19): 3474-3477				

	· · · · · · · · · · · · · · · · · · ·		1
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..